Status:
COMPLETED
Betamethasone and Severity of Hyaline Membrane Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pregnant Women Receive Celesten
Eligibility:
FEMALE
18+ years
Brief Summary
Primary purpose: to study the relationship between betamethasone placental transfer and the occurrence and severity of the Hyaline Membrane Disease.
Detailed Description
β-Mhyalines is a prospective multicentric non interventional study. One hundred fifty pregnant women at risk of premature delivery, in the framework of Hyaline Membrane Disease of the neonate, will re...
Eligibility Criteria
Inclusion
- Pregnant women who received at least a first injection of Celesten in the prevention of MMH.
- A one-term\> 27 SA,
- Major Patients \> or = 18 years old
- Informed Consent Form signed
Exclusion
- Patients undergoing treatment with corticosteroids in the long term
Key Trial Info
Start Date :
January 12 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT01854840
Start Date
January 12 2012
End Date
December 31 2018
Last Update
April 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necker Hospital
Paris, France, 75015